Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.55 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295172 | 0.91 | ADORA2A (0.65) | ADORA2AADORA2BADORA3ADORA1KDM4E | |
| SCHEMBL1081737 | 0.89 | ADORA2A (0.68) | ADORA2AADORA2BADORA3ADORA1KDM4E | |
| Hydrochloric Acid SCHEMBL6754869 | 0.89 | ADORA2A (0.68) | ADORA2AADORA2BADORA3ADORA1KDM4E | |
| Hydrochloric Acid SCHEMBL2031971 | 0.88 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1KDM4E | |
| SCHEMBL724837 | 0.86 | ADORA2A (0.58) | ADORA2AADORA2BADORA3ADORA1KDM4E | |
| SCHEMBL6852900 | 0.86 | ADORA2A (0.57) | ADORA2AADORA2BADORA3ADORA1KDM4E | |
| SCHEMBL5690282 | 0.85 | ADORA3 (0.39) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL1976908 | 0.81 | ADORA2A (0.56) | ADORA2AADORA2BADORA3ADORA1KDM4E | |
| Hydrochloric Acid SCHEMBL9247444 | 0.79 | ADORA2A (0.70) | ADORA2AADORA2BADORA3ADORA1KDM4E | |
| SCHEMBL5689446 | 0.78 | ADORA3 (0.40) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996453-B1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 2004-04-28 | — | — | EP | claimed |
| US-8338411-B2 | Compounds | SANOFI (FR) | 2012-12-25 | — | — | US | disclosed |
| EP-1390349-B1 | AMINOQUINOLINE AND AMINOPYRIDINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI SA (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-8071601-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-7964731-B2 | Isotopically marked quinoline derivatives as adenosin A3 receptor ligands | SANOFI-AVENTIS (FR) | 2011-06-21 | — | — | US | disclosed |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| EP-2167470-B1 | TRIAZOLO [1, 5-A]QUINOLINES AS ADENOSINE A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2011-03-16 | — | — | EP | disclosed |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-7799922-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2010-09-21 | — | — | US | disclosed |
| EP-1814857-B1 | ISOTOPICALLY MARKED QUINOLINE DERIVATIVES AS ADENOSIN A3 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2010-09-01 | — | — | EP | disclosed |
| US-20050124648-A1 | Triazolo-quinolin derivatives useful as adenosine receptor ligands | SANOFI-AVENTIS (FR) | 2005-06-09 | — | — | US | disclosed |
| US-20050070566-A1 | Imidazoquinoline derivatives | SANOFI-AVENTIS (FR) | 2005-03-31 | — | — | US | disclosed |
| EP-1456204-A1 | TRIAZOLO-QUINOLIN DERIVATIVES USEFUL AS ADENOSINE RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2004-09-15 | — | — | EP | disclosed |
| EP-1456205-A1 | IMIDAZOQUINOLINE DERIVATIVES | Sanofi-Aventis (FR) | 2004-09-15 | — | — | EP | disclosed |
| EP-0996453-B1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003053969-A1 | IMIDAZOQUINOLINE DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053968-A1 | TRIAZOLO-QUINOLIN DERIVATIVES USEFUL AS ADENOSINE RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2003-07-03 | — | — | WO | disclosed |
| US-6110902-A | IMPLANTING ENCAPSIDATED ADENOSINE RELEASING CELLS TO DELIVER A CONTINUOUS LOCAL DOSE OF ADENOSINE INTO THE BRAIN OF THE PATIENT | MOEHLER HANNS (CH) | 2000-08-29 | — | — | US | disclosed |
| EP-0996453-A1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | Mohler, Hanns (CH) | 2000-05-03 | — | — | EP | disclosed |
| WO-1998058653-A1 | METHODS FOR THE INHIBITION OF NEURONAL ACTIVITY BY LOCAL DELIVERY OF ADENOSINE | MOHLER HANNS (CH) | 1998-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070566-A1 | Imidazoquinoline derivatives | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 4/4885ADORA3 1/4885 |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA2B 3/4885ADORA3 1/4885 |
| US-20050124648-A1 | Triazolo-quinolin derivatives useful as adenosine receptor ligands | ADORA3, ADORA2A, ADORA1 | ADORA2A 2/4885ADORA2B 4/4885ADORA3 1/4885 |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | ADORA2A 2/4885ADORA2B 3/4885ADORA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.